← Back to Treatments
🏅 FDA Orphan Designation

CARNEXIV

intravenous carbamazepine

Manufacturer: Lundbeck LLC

Indicated for:
EAST syndromeOrphanAutosomal recessive complex spastic paraplegiaMixed functioning pituitary adenomaEpilepsy with generalized tonic-clonic seizures alone

FDA-Approved Indications (4)

EAST syndromeOrphan Designation

Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) Partial seizures with complex symptomolog…

Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with partial seizures with complex symptomology

Population: adults

Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with mixed seizure patterns which include partial or generalized seizures

Population: adults

Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with generalized tonic-clonic seizures

Population: adults

Indications & Usage

Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) Partial seizures with complex symptomology; (2)Generalized tonic-clonic seizures; and (3) Mixed seizure patterns which include the above or other partial or generalized seizures

💙 Support Programs

View all →
CARNEXIV
Lundbeck LLC
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.